{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:02:29Z","timestamp":1790920949113,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1038\/nrgastro.2009.102","type":"journal-article","created":{"date-parts":[[2009,7,3]],"date-time":"2009-07-03T10:39:02Z","timestamp":1246617542000},"page":"383-385","source":"Crossref","is-referenced-by-count":18,"title":["HCV variability, the immune system and resistance to antiviral drugs"],"prefix":"10.1038","volume":"6","author":[{"given":"Jean-Michel","family":"Pawlotsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrgastro2009102_CR1","first-page":"261","volume":"299","author":"JM Pawlotsky","year":"2006","unstructured":"Pawlotsky, J. M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 299, 261\u2013284 (2006).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"BFnrgastro2009102_CR2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMra025195","volume":"350","author":"F Clavel","year":"2004","unstructured":"Clavel, F. & Hance, A. J. HIV drug resistance. N. Engl. J. Med. 350, 1023\u20131035 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2009102_CR3","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1053\/j.gastro.2007.03.116","volume":"132","author":"JM Pawlotsky","year":"2007","unstructured":"Pawlotsky, J. M., Chevaliez, S. & McHutchison, J. G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132, 1979\u20131998 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009102_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin, C.  et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767\u20131777 (2007).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2009102_CR5","doi-asserted-by":"publisher","first-page":"49164","DOI":"10.1074\/jbc.M305041200","volume":"278","author":"G Migliaccio","year":"2003","unstructured":"Migliaccio, G.  et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278, 49164\u201349170 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrgastro2009102_CR6","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1128\/AAC.00433-06","volume":"50","author":"H Dutartre","year":"2006","unstructured":"Dutartre, H., Bussetta, C., Boretto, J. & Canard, B. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2\u2032-modified nucleotide analogues. Antimicrob. Agents Chemother. 50, 4161\u20134169 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"Suppl. 1","key":"BFnrgastro2009102_CR7","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1016\/S0168-8278(09)60090-8","volume":"50","author":"L Coelmont","year":"2009","unstructured":"Coelmont, L.  et al. Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor DEBIO-025. J. Hepatol. 50 (Suppl. 1), S36 (2009).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2009102_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/hep.22773","volume":"49","author":"S Gaudieri","year":"2009","unstructured":"Gaudieri, S.  et al. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49, 1069\u20131082 (2009).","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"BFnrgastro2009102_CR9","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/S0168-8278(09)60052-0","volume":"50","author":"GR Foster","year":"2009","unstructured":"Foster, G. R.  et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis C patients: interim results of study C209. J. Hepatol. 50 (Suppl. 1), S22 (2009).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"BFnrgastro2009102_CR10","doi-asserted-by":"publisher","first-page":"S384","DOI":"10.1016\/S0168-8278(09)61057-6","volume":"50","author":"E Lawitz","year":"2009","unstructured":"Lawitz, E.  et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J. Hepatol. 50 (Suppl. 1), S384 (2009).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2009102_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1128\/AAC.01598-08","volume":"53","author":"MF McCown","year":"2009","unstructured":"McCown, M. F., Rajyaguru, S., Kular, S., Cammack, N. & Najera, I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob. Agents Chemother. 53, 2129\u20132132 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrgastro2009102_CR12","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/hep.22549","volume":"48","author":"T Kuntzen","year":"2008","unstructured":"Kuntzen, T.  et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48, 1769\u20131778 (2008).","journal-title":"Hepatology"},{"key":"BFnrgastro2009102_CR13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1086\/591141","volume":"198","author":"DJ Bartels","year":"2008","unstructured":"Bartels, D. J.  et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3\/4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198, 800\u2013807 (2008).","journal-title":"J. Infect. Dis."},{"key":"BFnrgastro2009102_CR14","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","volume":"360","author":"C Hezode","year":"2009","unstructured":"Hezode, C.  et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839\u20131850 (2009).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2009.102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2009.102","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2009.102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:38:07Z","timestamp":1684467487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2009.102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["BFnrgastro2009102"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2009.102","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}